Halozyme Therapeutics, Inc. is a biotechnology company headquartered in San Diego, California, focused on enabling subcutaneous delivery of medicines. Its core ENHANZE drug delivery technology uses a recombinant human hyaluronidase enzyme (rHuPH20) to temporarily degrade hyaluronan in the extracellular matrix, allowing rapid administration and absorption of therapeutics that are otherwise given intravenously.
Halozyme partners with global biopharmaceutical companies to develop subcutaneous formulations of existing and new drugs across oncology, immunology, and rare diseases. The company generates revenue from licenses, milestones, and royalties tied to partner products that incorporate ENHANZE. Following the acquisition of Antares Pharma, Halozyme also provides auto-injector drug–device technologies and related manufacturing and commercialization capabilities. Halozyme is publicly listed on Nasdaq under the ticker HALO.